{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "exchange": "LSE", "shortName": "UNIQURE NV UNIQURE ORD SHS", "longName": "uniQure N.V.", "messageBoardId": "finmb_171029664", "market": "gb_market", "marketState": "CLOSED", "trailingAnnualDividendRate": 0.0, "trailingPE": 0.031757515, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": 6.887, "sharesOutstanding": 37247200, "bookValue": 10.135, "fiftyDayAverage": 21.722775, "fiftyDayAverageChange": 0.14862633, "fiftyDayAverageChangePercent": 0.006841959, "twoHundredDayAverage": 20.59571, "tradeable": false, "cryptoTradeable": false, "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "esgPopulated": false, "regularMarketChangePercent": -1.4801798, "regularMarketPrice": 21.8714, "regularMarketChange": -0.32859993, "regularMarketTime": 1683913613, "regularMarketDayHigh": 21.8714, "regularMarketDayRange": "21.7 - 21.8714", "regularMarketDayLow": 21.7, "regularMarketVolume": 300, "regularMarketPreviousClose": 22.2, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 21.7, "averageDailyVolume3Month": 479, "averageDailyVolume10Day": 523, "fiftyTwoWeekLowChange": 8.591401, "fiftyTwoWeekLowChangePercent": 0.64694285, "fiftyTwoWeekRange": "13.28 - 27.78", "fiftyTwoWeekHighChange": -5.9086, "fiftyTwoWeekHighChangePercent": -0.21269257, "fiftyTwoWeekLow": 13.28, "fiftyTwoWeekHigh": 27.78, "twoHundredDayAverageChange": 1.2756901, "twoHundredDayAverageChangePercent": 0.0619396, "marketCap": 8386894, "priceToBook": 2.158007, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "firstTradeDateMilliseconds": 1517212800000, "priceHint": 2, "symbol": "0EE0.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Paasheuvelweg 25", "city": "Amsterdam", "zip": "1105 BP", "country": "Netherlands", "phone": "31 20 240 6000", "website": "https://www.uniqure.com", "industry": "", "sector": "", "longBusinessSummary": "uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.", "fullTimeEmployees": 501, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew Craig Kapusta", "age": 50, "title": "CEO & Exec. Director", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 1157887, "fmt": "1.16M", "longFmt": "1,157,887"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 4726089, "fmt": "4.73M", "longFmt": "4,726,089"}}, {"maxAge": 1, "name": "Mr. Christian  Klemt", "age": 49, "title": "CFO, Principal Financial Officer & GM of Amsterdam Site", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 566360, "fmt": "566.36k", "longFmt": "566,360"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 362614, "fmt": "362.61k", "longFmt": "362,614"}}, {"maxAge": 1, "name": "Mr. Pierre  Caloz", "age": 50, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": {"raw": 951104, "fmt": "951.1k", "longFmt": "951,104"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Ricardo  Dolmetsch Ph.D.", "age": 53, "title": "Pres of R&D", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 911070, "fmt": "911.07k", "longFmt": "911,070"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Prof. Hugo  Katus", "title": "Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David  Cerveny", "age": 55, "title": "Chief Legal Officer, Gen. Counsel & Sec.", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tamara  Tugal Ph.D., MBA", "title": "Bus. Devel. Director", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Erin  Boyer", "title": "Chief People & Culture Office", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Maria E. Cantor", "age": 54, "title": "Chief Corp. Affairs Officer", "yearBorn": 1968, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Richard  Porter Ph.D.", "title": "Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 3, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}